Outcomes
CRS, Cancer
ADVERSE EVENT, CANCER
For dose escalation (part 1), the primary endpoint was the number of DLTs. The primary efficacy endpoints were ORR and DOR for patients treated at efficacious doses, with response assessed according to IMWG criteriaThe DLT observation period was through the end of the first treatment cycle for each patient in part 1. TEAEs were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Both CRS and ICANS were defined and graded according to American Society for Transplantation and Cellular Therapy consensus criteria